# reload+after+2024-01-23 20:45:03.994841
address1§Parc EurasantE
address2§885, avenue EugEne AvinEe
city§Loos
zip§59120
country§France
phone§33 3 20 16 40 00
fax§33 2 20 16 40 01
website§https://www.genfit.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
fullTimeEmployees§154
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Jean-Francois  Mouney', 'age': 68, 'title': 'Co-Founder & Chairman of the Board', 'yearBorn': 1955, 'fiscalYear': 2022, 'totalPay': 403778, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. M. Pascal Prigent', 'age': 55, 'title': 'Chief Executive Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 611941, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Prof. Bart  Staels', 'age': 60, 'title': 'Co-Founder & Chairman of the Scientific Advisory Board', 'yearBorn': 1963, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Thomas  Baetz', 'age': 49, 'title': 'Chief Financial Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Pascal  Caisey', 'age': 55, 'title': 'Chief Operating Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Meriam  Kabbaj Ph.D.', 'age': 49, 'title': 'Chief Technology Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Dean W. Hum Ph.D.', 'age': 61, 'title': 'Chief Scientific Officer', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 778662, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jean-Christophe  Marcoux', 'age': 45, 'title': 'Chief Corporate Affairs Officer, Head of Investor Relations & Head of ESG', 'yearBorn': 1978, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Laurent  Lannoo', 'age': 53, 'title': 'Corporate Secretary & Director of Legal Affairs', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Stefanie  Magner J.D.', 'age': 42, 'title': 'Chief Compliance Officer & Executive VP of International Legal Affairs', 'yearBorn': 1981, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§7
compensationRisk§3
shareHolderRightsRisk§5
overallRisk§5
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.893
priceToSalesTrailing12Months§6.923386
currency§USD
dateShortInterest§1702598400
exchange§NMS
quoteType§EQUITY
shortName§GENFIT S.A.
longName§Genfit S.A.
firstTradeDateEpochUtc§1553693400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§8eb2c194-ee16-3906-8e8c-31a65bed07c5
gmtOffSetMilliseconds§-18000000
recommendationKey§none
quickRatio§2.891
grossMargins§1.0
ebitdaMargins§-1.07653
trailingPegRatio§None
